Literature DB >> 30978357

Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development.

Joachim Lupberger1, Tom Croonenborghs2, Armando Andres Roca Suarez3, Nicolaas Van Renne3, Frank Jühling3, Marine A Oudot3, Alessia Virzì3, Simonetta Bandiera3, Carole Jamey4, Gergö Meszaros5, Daniel Brumaru4, Atish Mukherji3, Sarah C Durand3, Laura Heydmann3, Eloi R Verrier3, Hussein El Saghire3, Nourdine Hamdane3, Ralf Bartenschlager6, Shaunt Fereshetian7, Evelyn Ramberger8, Rileen Sinha2, Mohsen Nabian2, Celine Everaert2, Marko Jovanovic9, Philipp Mertins10, Steven A Carr7, Kazuaki Chayama11, Nassim Dali-Youcef12, Romeo Ricci5, Nabeel M Bardeesy13, Naoto Fujiwara14, Olivier Gevaert15, Mirjam B Zeisel3, Yujin Hoshida14, Nathalie Pochet16, Thomas F Baumert17.   

Abstract

BACKGROUND & AIMS: The mechanisms of hepatitis C virus (HCV) infection, liver disease progression, and hepatocarcinogenesis are only partially understood. We performed genomic, proteomic, and metabolomic analyses of HCV-infected cells and chimeric mice to learn more about these processes.
METHODS: Huh7.5.1dif (hepatocyte-like cells) were infected with culture-derived HCV and used in RNA sequencing, proteomic, metabolomic, and integrative genomic analyses. uPA/SCID (urokinase-type plasminogen activator/severe combined immunodeficiency) mice were injected with serum from HCV-infected patients; 8 weeks later, liver tissues were collected and analyzed by RNA sequencing and proteomics. Using differential expression, gene set enrichment analyses, and protein interaction mapping, we identified pathways that changed in response to HCV infection. We validated our findings in studies of liver tissues from 216 patients with HCV infection and early-stage cirrhosis and paired biopsy specimens from 99 patients with hepatocellular carcinoma, including 17 patients with histologic features of steatohepatitis. Cirrhotic liver tissues from patients with HCV infection were classified into 2 groups based on relative peroxisome function; outcomes assessed included Child-Pugh class, development of hepatocellular carcinoma, survival, and steatohepatitis. Hepatocellular carcinomas were classified according to steatohepatitis; the outcome was relative peroxisomal function.
RESULTS: We quantified 21,950 messenger RNAs (mRNAs) and 8297 proteins in HCV-infected cells. Upon HCV infection of hepatocyte-like cells and chimeric mice, we observed significant changes in levels of mRNAs and proteins involved in metabolism and hepatocarcinogenesis. HCV infection of hepatocyte-like cells significantly increased levels of the mRNAs, but not proteins, that regulate the innate immune response; we believe this was due to the inhibition of translation in these cells. HCV infection of hepatocyte-like cells increased glucose consumption and metabolism and the STAT3 signaling pathway and reduced peroxisome function. Peroxisomes mediate β-oxidation of very long-chain fatty acids; we found intracellular accumulation of very long-chain fatty acids in HCV-infected cells, which is also observed in patients with fatty liver disease. Cells in livers from HCV-infected mice had significant reductions in levels of the mRNAs and proteins associated with peroxisome function, indicating perturbation of peroxisomes. We found that defects in peroxisome function were associated with outcomes and features of HCV-associated cirrhosis, fatty liver disease, and hepatocellular carcinoma in patients.
CONCLUSIONS: We performed combined transcriptome, proteome, and metabolome analyses of liver tissues from HCV-infected hepatocyte-like cells and HCV-infected mice. We found that HCV infection increases glucose metabolism and the STAT3 signaling pathway and thereby reduces peroxisome function; alterations in the expression levels of peroxisome genes were associated with outcomes of patients with liver diseases. These findings provide insights into liver disease pathogenesis and might be used to identify new therapeutic targets.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HCC; immune regulation; metabolic disease; signal transduction

Mesh:

Substances:

Year:  2019        PMID: 30978357      PMCID: PMC8318381          DOI: 10.1053/j.gastro.2019.04.003

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  60 in total

Review 1.  Peroxisomes: a nexus for lipid metabolism and cellular signaling.

Authors:  Irfan J Lodhi; Clay F Semenkovich
Journal:  Cell Metab       Date:  2014-02-06       Impact factor: 27.287

2.  The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation.

Authors:  Monica Buzzai; Daniel E Bauer; Russell G Jones; Ralph J Deberardinis; Georgia Hatzivassiliou; Rebecca L Elstrom; Craig B Thompson
Journal:  Oncogene       Date:  2005-06-16       Impact factor: 9.867

3.  Deep, Quantitative Coverage of the Lysine Acetylome Using Novel Anti-acetyl-lysine Antibodies and an Optimized Proteomic Workflow.

Authors:  Tanya Svinkina; Hongbo Gu; Jeffrey C Silva; Philipp Mertins; Jana Qiao; Shaunt Fereshetian; Jacob D Jaffe; Eric Kuhn; Namrata D Udeshi; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2015-05-07       Impact factor: 5.911

4.  Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation.

Authors:  Urtzi Garaigorta; Francis V Chisari
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

Review 5.  Mechanisms of NAFLD development and therapeutic strategies.

Authors:  Scott L Friedman; Brent A Neuschwander-Tetri; Mary Rinella; Arun J Sanyal
Journal:  Nat Med       Date:  2018-07-02       Impact factor: 53.440

6.  Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A.

Authors:  Marie-Sophie Hiet; Oliver Bauhofer; Margarita Zayas; Hanna Roth; Yasuhito Tanaka; Peter Schirmacher; Joschka Willemsen; Oliver Grünvogel; Silke Bender; Marco Binder; Volker Lohmann; Vincent Lotteau; Alessia Ruggieri; Ralf Bartenschlager
Journal:  J Hepatol       Date:  2015-04-20       Impact factor: 25.083

7.  Immunogenetics. Dynamic profiling of the protein life cycle in response to pathogens.

Authors:  Marko Jovanovic; Michael S Rooney; Philipp Mertins; Dariusz Przybylski; Nicolas Chevrier; Rahul Satija; Edwin H Rodriguez; Alexander P Fields; Schraga Schwartz; Raktima Raychowdhury; Maxwell R Mumbach; Thomas Eisenhaure; Michal Rabani; Dave Gennert; Diana Lu; Toni Delorey; Jonathan S Weissman; Steven A Carr; Nir Hacohen; Aviv Regev
Journal:  Science       Date:  2015-02-12       Impact factor: 47.728

Review 8.  Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect.

Authors:  Iñigo San-Millán; George A Brooks
Journal:  Carcinogenesis       Date:  2017-02-01       Impact factor: 4.944

9.  Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics.

Authors:  Deborah L Diamond; Andrew J Syder; Jon M Jacobs; Christina M Sorensen; Kathie-Anne Walters; Sean C Proll; Jason E McDermott; Marina A Gritsenko; Qibin Zhang; Rui Zhao; Thomas O Metz; David G Camp; Katrina M Waters; Richard D Smith; Charles M Rice; Michael G Katze
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

10.  Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.

Authors:  Fei Xiao; Isabel Fofana; Laura Heydmann; Heidi Barth; Eric Soulier; François Habersetzer; Michel Doffoël; Jens Bukh; Arvind H Patel; Mirjam B Zeisel; Thomas F Baumert
Journal:  PLoS Pathog       Date:  2014-05-15       Impact factor: 6.823

View more
  24 in total

Review 1.  Reprogramming of cellular metabolic pathways by human oncogenic viruses.

Authors:  John G Purdy; Micah A Luftig
Journal:  Curr Opin Virol       Date:  2019-11-22       Impact factor: 7.090

Review 2.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

Review 3.  Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies.

Authors:  N Merchante; M Rodríguez-Fernández; J A Pineda
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

4.  Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome.

Authors:  Lauren E Ball; Bernice Agana; Susana Comte-Walters; Don C Rockey; Henry Masur; Shyam Kottilil; Eric G Meissner
Journal:  J Viral Hepat       Date:  2021-08-19       Impact factor: 3.728

Review 5.  A systems approach to infectious disease.

Authors:  Manon Eckhardt; Judd F Hultquist; Robyn M Kaake; Ruth Hüttenhain; Nevan J Krogan
Journal:  Nat Rev Genet       Date:  2020-02-14       Impact factor: 53.242

6.  Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial.

Authors:  Antonio Saviano; François Habersetzer; Joachim Lupberger; Pauline Simo-Noumbissie; Catherine Schuster; Michel Doffoël; Catherine Schmidt-Mutter; Thomas F Baumert
Journal:  Clin Transl Gastroenterol       Date:  2022-06-01       Impact factor: 4.396

Review 7.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

Review 8.  Whole Lotta Lipids-from HCV RNA Replication to the Mature Viral Particle.

Authors:  Hanna Bley; Anja Schöbel; Eva Herker
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

Review 9.  Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip.

Authors:  Kaku Goto; Armando Andres Roca Suarez; Florian Wrensch; Thomas F Baumert; Joachim Lupberger
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 10.  Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.

Authors:  Alessia Virzì; Armando Andres Roca Suarez; Thomas F Baumert; Joachim Lupberger
Journal:  Cold Spring Harb Perspect Med       Date:  2020-01-02       Impact factor: 5.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.